Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

BUPA Launches Breakthrough Treatment For Back And Knee Pain
New research reveals around 22 million people suffered back pain in the last year - just under half of all UK adults (45 percent)[1]. More than one in four UK adults - nearly 13 million people - suffered from knee pain in the last year. Over 80 percent of the people with back or knee pain still suffer some pain after undergoing treatment recommended by a healthcare professional. Bupa is making APOS Treatment for knee and lower back pain available in the UK for the first time. The breakthrough treatment can eliminate the need for prescription pain relief for seven out of 10 people[2].
generic viagra online
San Francisco Organizations Urge Lawmakers To Restore HIV/AIDS Funding, Plan Rally
San Francisco area HIV/AIDS organizations are urging lawmakers to restore millions of dollars in funding for HIV/AIDS prevention and treatment programs that were cut from the California budget by Gov. Arnold Schwarzenegger (R) this week, KCBS.com reports. "The governor has removed a substantial amount of our capacity to make sure that people know their HIV status," Dana Van Gorder of Project Inform said, adding "Services that are keeping people who are already HIV positive healthy will be reduced with a major impact on their health." A rally is planned to take place next week at the state building in San Francisco to protest the cuts, according to the article (7/30). David Brinkman of the Desert AIDS Project in Palm Springs, "says the budget cuts are literally a matter of life and death," KESQ.com reports. The Desert AIDS Project is hoping that planned fundraising will temporarily offset the cuts to services in the Palm Springs area (Diaz, 7/30).
News of the day
Take Precautions To Prevent Heat Illnesses, Alabama Dept. Of Health
Alabama"s summer climate with its extreme temperatures and high humidity can lead to heatrelated
Diagnostics

Collaborative Drug Discovery Partnership To Advance Cancer Drug Development

SRI International, an independent nonprofit research and development organization, has announced that SRI"s Center for Cancer Research was selected by the National Cancer Institute (NCI) for a leading role in the newly-formed "Chemical Biology Consortium" (CBC), a collaborative drug discovery partnership focused on advancing new cancer therapeutics active against novel molecular and genetic cancer targets. Based on its track record of cancer drug discovery and development, SRI was chosen to lead three of the CBC"s research and development centers: Comprehensive Chemical Biology Screening, Chemical Diversity, and Specialized Applications. SRI has decades of experience in successfully identifying, developing and advancing novel compounds into clinical evaluation. SRI"s Center for Cancer Research, comprised of biologists and medicinal chemists with expertise in fundamental and applied cancer research, focuses on the study of tumor microenvironment, tumor metabolism, and aberrant signaling pathways that cause cancer. Through collaborative partnerships, SRI"s Center for Cancer Research has been successful in generating an extensive drug pipeline translating discoveries into beneficial treatments. SRI"s drug discovery process, guided by a combination of biological screens and computational methods, will be a key component of the NCI Chemical Biology Consortium program. "SRI is proud to be selected to join this innovative NCI program and to continue our long-standing support of NCI"s mission to discover, develop, and bring new drugs to cancer patients," said Lidia Sambucetti, Ph.D., senior director of SRI"s Center for Cancer Research. "Our multidisciplinary research team will bring proven expertise in fundamental and applied cancer research, backed by SRI"s fully-integrated preclinical capabilities." The goal of the Chemical Biology Consortium is to discover and develop new cancer therapeutics, particularly those that are beyond the scope of standard biopharmaceutical practice. The CBC will focus on therapeutic opportunities in high-risk, under-represented areas to advance the discovery of compounds active against novel molecular and genetic cancer targets. Sambucetti will serve as the overall principal investigator of SRI"s CBC program and the Comprehensive Chemical Biology Screening Center. She will collaborate with Mary Tanga, Ph.D., an SRI senior director of medicinal chemistry, who will lead the Chemical Diversity Center, and Keith Laderoute, Ph.D., an SRI distinguished scientist, who will lead the Specialized Applications Center. As the principal investigator of the Comprehensive Chemical Biology Screening Center, Sambucetti was invited to join the CBC Steering Committee, an NCI advisory panel that will work to ensure that CBC Centers are efficiently bridging the gap between basic scientific findings and NCI-supported clinical research. To optimize high-quality leads and accelerate the drug discovery process, SRI will be working with BioComputing Group, Inc., a developer of computational screening, hit-to-lead, and lead optimization tools with particular emphasis on structure-guided drug discovery. These tools employ novel molecular descriptors that are derived from active compounds within the target family and from the structure of the target protein that can be applied to the evaluation of compounds from a library as well as compounds not yet synthesized. BioComputing Group, Inc. (www.BioPredict.com) has a significant track record of success in applying its tools in a hypothesis-driven paradigm to accelerate drug discovery efforts of its collaborators and clients, having placed multiple compounds into clinic with significantly reduced numbers of compounds screened and synthesized and with significantly shortened time frames. This project has been funded in whole or in part with Federal Funds from the National Cancer Institute, National Institutes of Health, under Contract No. N01-C0-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. Dina Basin SRI International


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009